About Emerivo
We are defining a new category: AI Visibility for Pharmaceutical Manufacturers.
Emerivo is not an AI company, an SEO agency, or a digital marketing firm. We are a specialist commercial visibility partner for pharmaceutical manufacturing and research organisations — built around one belief: AI has become the first stage of supplier discovery, and it is currently invisible to most companies.
Two terms are worth distinguishing up front. AI Visibility is the customer-facing category — whether AI can find, understand and recommend your organisation at all. AI Discovery Methodology™ is Emerivo's own proprietary methodology for improving it: the specific audits, frameworks and execution behind every engagement.
Our purpose
Why we exist
Emerivo exists to make pharmaceutical manufacturers and research organisations easy for AI to discover, understand and recommend — so genuine capability, not existing familiarity, is what determines who gets found.
Our mission
To make it possible for pharmaceutical manufacturers and research organisations to be judged by AI on genuine capability — not on which names AI already happens to recognise.
Our vision
A market where AI understands and represents specialist pharmaceutical partners with the same accuracy and nuance a well-briefed buyer would expect from a direct conversation.
The Shift We Observed
Why partner discovery changed — and why Emerivo exists
For decades, partner discovery in pharmaceutical manufacturing and research ran on trade shows, industry referrals and Google search. A commercial team would search for a capability, visit several websites, and build a shortlist by hand.
Then AI changed the process. Sourcing teams, procurement managers and business development heads no longer start with a search engine — they ask an AI assistant directly. A typical prompt today looks like this:
AI responds with a shortlist of three or four companies. If a supplier isn’t on that list, they are excluded from the opportunity before a single conversation takes place — not because they lacked the capability, but because AI could not find them, understand them, or represent them accurately.
This is the problem Emerivo was built to solve.
Our position
AI is the mechanism. Commercial growth is the outcome.
We don’t position ourselves around AI technology because AI is not the point. The point is that buyers — procurement leads, sourcing teams, commercial and BD heads — are changing how they find manufacturing and research partners, and that shift has direct commercial consequences for suppliers who are hard for AI to understand.
Everything we build, from our methodology to our published research, exists to answer one question on behalf of our clients: when a buyer asks AI to recommend a partner like you, does AI confidently include you — and describe you correctly?
Why a new category
Not AI consulting. Not SEO. Not marketing.
Pharmaceutical partner discovery is highly specialised, highly regulated, and easy for generalist agencies to get wrong. We built Emerivo specifically to close the gap between how pharmaceutical manufacturing and research organisations actually operate, and how clearly AI models are currently able to understand that.
That requires proprietary methodology, original research, and hands-on execution — not a generic playbook borrowed from another industry.
Why Emerivo
What makes Emerivo different
Specialised for Pharmaceutical Organisations
We work exclusively with TPMs, CMOs, CDMOs and CROs. Pharmaceutical manufacturing and research is a highly specific domain — regulatory nuance, certifications and buyer language all matter, and generalist agencies routinely miss them.
We Execute
We do not hand over a slide deck and disappear. Our team restructures websites, rewrites content and implements the changes required to improve AI understanding — from strategy through to execution.
Continuous Monitoring
AI models are updated constantly, and buyer questions evolve. We continuously re-test your visibility and keep refining your positioning, rather than treating AI visibility as a one-time project.
Our approach
How we work with you
AI Discovery Audit™
We show you exactly how AI currently finds, understands and describes your organisation against real buyer prompts.
AI Discovery Blueprint™
We build a tailored plan to close the gaps between what you offer and what AI can currently understand.
AI Discovery Implementation™
We restructure content and capability information so AI represents you accurately and specifically.
AI Discovery Monitoring™
We re-test your AI visibility continuously as AI models and buyer questions evolve.
Knowledge-first, by design
Our research and methodology are published — not locked behind a sales call
We treat original research, our AI Discovery Reports™, and our Knowledge Hub as strategic assets in their own right — proof of the methodology, available before any commercial conversation begins. Services are the practical application of that knowledge, not a substitute for it.
About the company
Who’s behind Emerivo
Emerivo is operated by PGSRE Consulting Private Limited, and works exclusively with Third-Party Manufacturers, CMOs, CDMOs and CROs in pharmaceutical manufacturing and research.
We do not serve buyers, and we do not serve every industry. That focus is deliberate: it is what allows us to build genuine domain expertise rather than generalist knowledge spread thin across unrelated sectors.
See whether AI recommends your company when buyers search for a partner
Request an AI Discovery Audit™ and get a clear, evidence-based view of where you stand today.